U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Pulmonary infiltrates

MedGen UID:
116009
Concept ID:
C0235896
Finding; Finding
Synonym: Lung infiltrates
 
HPO: HP:0002113

Definition

A finding indicating the presence of an inflammatory or neoplastic cellular infiltrate in the lung parenchyma. [from NCI]

Conditions with this feature

Letterer-Siwe disease
MedGen UID:
7311
Concept ID:
C0023381
Disease or Syndrome
A multifocal, multisystem form of Langerhans-cell histiocytosis. There is involvement of multiple organ systems including the bones, skin, liver, spleen, and lymph nodes. Patients are usually infants presenting with fever, hepatosplenomegaly, lymphadenopathy, bone and skin lesions, and pancytopenia.
Idiopathic hypereosinophilic syndrome
MedGen UID:
61525
Concept ID:
C0206141
Disease or Syndrome
PDGFRA-associated chronic eosinophilic leukemia is a form of blood cell cancer characterized by an elevated number of cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRA-associated chronic eosinophilic leukemia.\n\nAnother characteristic feature of PDGFRA-associated chronic eosinophilic leukemia is organ damage caused by the excess eosinophils. Eosinophils release substances to aid in the immune response, but the release of excessive amounts of these substances causes damage to one or more organs, most commonly the heart, skin, lungs, or nervous system. Eosinophil-associated organ damage can lead to a heart condition known as eosinophilic endomyocardial disease, skin rashes, coughing, difficulty breathing, swelling (edema) in the lower limbs, confusion, changes in behavior, or impaired movement or sensations. People with PDGFRA-associated chronic eosinophilic leukemia can also have an enlarged spleen (splenomegaly) and elevated levels of certain chemicals called vitamin B12 and tryptase in the blood.\n\nSome people with PDGFRA-associated chronic eosinophilic leukemia have an increased number of other types of white blood cells, such as neutrophils or mast cells. Occasionally, people with PDGFRA-associated chronic eosinophilic leukemia develop other blood cell cancers, such as acute myeloid leukemia or B-cell or T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.\n\nPDGFRA-associated chronic eosinophilic leukemia is often grouped with a related condition called hypereosinophilic syndrome. These two conditions have very similar signs and symptoms; however, the cause of hypereosinophilic syndrome is unknown.
Familial eosinophilia
MedGen UID:
78796
Concept ID:
C0272192
Disease or Syndrome
Familial eosinophilia is a rare autosomal dominant disorder characterized by peripheral hypereosinophilia (greater than 500 eosinophils/micro liter of blood) with or without other oragn involvement (summary by Rioux et al., 1998).
Lipochrome histiocytosis - familial
MedGen UID:
90743
Concept ID:
C0334125
Disease or Syndrome
Anti-glomerular basement membrane disease
MedGen UID:
140788
Concept ID:
C0403529
Disease or Syndrome
Goodpasture syndrome, also known as anti-GBM disease, is a rare autoimmune disease consisting of alveolar hemorrhage and glomerulonephritis secondary to circulating antiglomerular basement membrane (anti-GBM) antibodies. Anti-GBM antibodies are directed against an antigen intrinsic to the alpha-3 chain of type IV collagen (COL4A3; 120070) that is expressed in the GBMs of the glomerular capillary loops and the basal membrane of the pulmonary alveoli. Goodpasture syndrome is suspected in patients with hemoptysis and hematuria and is confirmed by the presence of anti-GBM antibodies in renal biopsy specimens and serum. Patients with human leukocyte antigen HLA-DR15 and HLA-DR4 are susceptible to the development of Goodpasture syndrome. Reported cases of familial Goodpasture syndrome are extremely rare (summary by Angioi et al., 2017).
Immunodeficiency due to CD25 deficiency
MedGen UID:
377894
Concept ID:
C1853392
Disease or Syndrome
Immunodeficiency-41 is an autosomal recessive complex disorder of immune dysregulation. Affected individuals present in infancy with recurrent viral, fungal, and bacterial infections, lymphadenopathy, and variable autoimmune features, such as autoimmune enteropathy and eczematous skin lesions. Immunologic studies show a defect in T-cell regulation (summary by Goudy et al., 2013).
Gaucher disease type I
MedGen UID:
409531
Concept ID:
C1961835
Disease or Syndrome
Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.
Brain-lung-thyroid syndrome
MedGen UID:
369694
Concept ID:
C1970269
Disease or Syndrome
NKX2-1-related disorders range from benign hereditary chorea (BHC) to choreoathetosis, congenital hypothyroidism, and neonatal respiratory distress (also known as brain-lung-thyroid syndrome). Childhood-onset chorea, the hallmark of NKX2-1-related disorders, may or may not be associated with respiratory distress syndrome or congenital hypothyroidism. Chorea generally begins in early infancy or about age one year (most commonly) or in late childhood or adolescence, and progresses into the second decade after which it remains static or (rarely) remits. Pulmonary disease, the second most common manifestation, can include respiratory distress syndrome in neonates, interstitial lung disease in young children, and pulmonary fibrosis in older persons. The risk for pulmonary carcinoma is increased in young adults with an NKX2-1-related disorder. Thyroid dysfunction, the result of dysembryogenesis, can present as congenital hypothyroidism or compensated hypothyroidism. The risk for thyroid cancer is unknown and may not be increased. In one review, 50% of affected individuals had the full brain-lung-thyroid syndrome, 30% had involvement of brain and thyroid only, and 13% had isolated chorea only.
Sarcoidosis, susceptibility to, 2
MedGen UID:
436694
Concept ID:
C2676468
Finding
Any sarcoidosis in which the cause of the disease is a mutation in the BTNL2 gene.
Sarcoidosis, susceptibility to, 1
MedGen UID:
394568
Concept ID:
C2697310
Finding
Any sarcoidosis in which the cause of the disease is a mutation in the HLA-DRB1 gene.
Granulomatosis with polyangiitis
MedGen UID:
811223
Concept ID:
C3495801
Disease or Syndrome
Granulomatosis with polyangiitis, formerly termed Wegener granulomatosis, is a systemic disease with a complex genetic background. It is characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tract, glomerulonephritis, vasculitis, and the presence of antineutrophil cytoplasmatic autoantibodies (ANCAs) in patient sera. These ANCAs are antibodies to a defined target antigen, proteinase-3 (PR3, PRTN3; 177020), which is present within primary azurophil granules of neutrophils (PMNs) and lysozymes of monocytes. On cytokine priming of PMNs, PR3 translocates to the cell surface, where PR3-ANCAs can interact with their antigens and activate PMNs. PMNs from patients with active GPA express PR3 on their surface, produce respiratory burst, and release proteolytic enzymes after activation with PR3-ANCAs. The consequence is a self-sustaining inflammatory process (Jagiello et al., 2004).
Immunodeficiency 27A
MedGen UID:
860386
Concept ID:
C4011949
Disease or Syndrome
Immunodeficiency-27A (IMD27A) results from autosomal recessive (AR) IFNGR1 deficiency. Patients with complete IFNGR1 deficiency have a severe clinical phenotype characterized by early and often fatal mycobacterial infections. The disorder can thus be categorized as a form of mendelian susceptibility to mycobacterial disease (MSMD). Bacillus Calmette-Guerin (BCG) and environmental mycobacteria are the most frequent pathogens, and infection typically begins before the age of 3 years. Plasma from patients with complete AR IFNGR1 deficiency usually contains large amounts of IFNG (147570), and their cells do not respond to IFNG in vitro. In contrast, cells from patients with partial AR IFNGR1 deficiency, which is caused by a specific mutation in IFNGR1, retain residual responses to high IFNG concentrations. Patients with partial AR IFNGR1 deficiency are susceptible to BCG and environmental mycobacteria, but they have a milder clinical disease and better prognosis than patients with complete AR IFNGR1 deficiency. The clinical features of children with complete AR IFNGR1 deficiency are usually more severe than those in individuals with AD IFNGR1 deficiency (IMD27B), and mycobacterial infection often occurs earlier (mean age of 1.3 years vs 13.4 years), with patients having shorter mean disease-free survival. Salmonellosis is present in about 5% of patients with AR or AD IFNGR1 deficiency, and other infections have been reported in single patients (review by Al-Muhsen and Casanova, 2008).
DOCK2 deficiency
MedGen UID:
901370
Concept ID:
C4225328
Disease or Syndrome
Immunodeficiency-40 is an autosomal recessive primary form of combined immunodeficiency mainly affecting T-cell number and function, with other more variable defects in B-cell and NK-cell function. Patients have onset of severe invasive bacterial and viral infections in early childhood and may die without bone marrow transplantation (summary by Dobbs et al., 2015).
Immunodeficiency 60
MedGen UID:
1681890
Concept ID:
C5193072
Disease or Syndrome
Immunodeficiency-60 and autoimmunity (IMD60) is an autosomal dominant primary immunologic disorder characterized by inflammatory bowel disease and recurrent sinopulmonary infections. The age at symptom onset is highly variable, ranging from infancy to mid-adulthood. Laboratory studies show dysregulation of both B and T cells, with variably decreased immunoglobulin production, decreased T-regulatory cells, and overall impaired lymphocyte maturation (summary by Afzali et al., 2017).
VEXAS syndrome
MedGen UID:
1765785
Concept ID:
C5435753
Disease or Syndrome
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) is an adult-onset inflammatory disease that primarily affects males and is caused by somatic, not germline, mutations. The disorder is characterized by adult onset of rheumatologic symptoms at a mean age of 64 years. Features include recurrent fevers, pulmonary and dermatologic inflammatory manifestations, vasculitis, deep vein thrombosis, arthralgias, and ear and nose chondritis. Laboratory studies indicate hematologic abnormalities, including macrocytic anemia, as well as increased levels of acute-phase reactants; about half of patients have positive autoantibodies. Bone marrow biopsy shows degenerative vacuolization restricted to myeloid and erythroid precursor cells, as well as variable hematopoietic dyspoiesis and dysplasias. The condition does not respond to rheumatologic medications and the features may result in premature death (summary by Beck et al., 2020).
Nephronophthisis-like nephropathy 2
MedGen UID:
1794163
Concept ID:
C5561953
Disease or Syndrome
Nephronophthisis-like nephropathy-2 (NPHPL2) is an autosomal recessive cystic kidney disease characterized by onset of progressive renal insufficiency in the first decades of life. Renal imaging and biopsy show corticomedullary cysts, tubular ectasia, tubular basement membrane disruption, and tubulointerstitial infiltrations. Patients eventually progress to end-stage renal failure, necessitating kidney transplantation or dialysis (summary by Hurd et al., 2013). For a general phenotypic description and a discussion of genetic heterogeneity of nephronophthisis, see NPHP1 (256100).
Primordial dwarfism-immunodeficiency-lipodystrophy syndrome
MedGen UID:
1823971
Concept ID:
C5774198
Disease or Syndrome
Primordial dwarfism-immunodeficiency-lipodystrophy syndrome (PDIL) is characterized by pre- and postnatal growth restriction, with extreme microcephaly, short stature, and absence of subcutaneous fat. There is also significant hematologic/immune dysfunction, with hypo- or agammaglobulinemia, as well as lymphopenia, anemia, and thrombocytopenia, and most affected individuals succumb to infection in early childhood (Parry et al., 2020).

Professional guidelines

PubMed

Agarwal R, Muthu V, Sehgal IS
Semin Respir Crit Care Med 2024 Feb;45(1):114-127. Epub 2023 Dec 28 doi: 10.1055/s-0043-1776912. PMID: 38154470
Tabb ES, Duncan LM, Nazarian RM
Am J Dermatopathol 2022 May 1;44(5):315-320. doi: 10.1097/DAD.0000000000002106. PMID: 35427287
De Giacomi F, Vassallo R, Yi ES, Ryu JH
Am J Respir Crit Care Med 2018 Mar 15;197(6):728-736. doi: 10.1164/rccm.201710-1967CI. PMID: 29206477

Recent clinical studies

Etiology

Hines AS, Mohandesi NA, Lehman JS, Koster MJ, Cantwell HM, Alavi A, Warrington KJ, Mangaonkar AA, Go RS, Patnaik MM, Sartori-Valinotti JC
Int J Dermatol 2023 Jul;62(7):938-945. Epub 2023 Mar 8 doi: 10.1111/ijd.16635. PMID: 36890121
Hoy RF, Chambers DC
Allergy 2020 Nov;75(11):2805-2817. Epub 2020 Feb 15 doi: 10.1111/all.14202. PMID: 31989662
Umbrello M, Formenti P, Bolgiaghi L, Chiumello D
Int J Mol Sci 2016 Dec 29;18(1) doi: 10.3390/ijms18010064. PMID: 28036088Free PMC Article
Itkin M, McCormack FX
Clin Chest Med 2016 Sep;37(3):409-20. doi: 10.1016/j.ccm.2016.04.004. PMID: 27514588
Marchand E, Cordier JF
Orphanet J Rare Dis 2006 Apr 6;1:11. doi: 10.1186/1750-1172-1-11. PMID: 16722612Free PMC Article

Diagnosis

Wetzler L, Klion AD
J Allergy Clin Immunol Pract 2024 Feb;12(2):530-532.e18. Epub 2023 Nov 19 doi: 10.1016/j.jaip.2023.11.020. PMID: 37984795Free PMC Article
Itkin M, McCormack FX
Clin Chest Med 2016 Sep;37(3):409-20. doi: 10.1016/j.ccm.2016.04.004. PMID: 27514588
Jayaprakash B, Sandhya S, Anithakumari K
J Assoc Physicians India 2009 Jul;57:535-6. PMID: 20329418
Zelitch SR, Israel HL
Am Fam Physician 1988 Aug;38(2):127-39. PMID: 3044050
Bodey GP
Chest 1979 Mar;75(3):298-9. doi: 10.1378/chest.75.3.298. PMID: 421570

Therapy

Taha HR, Keewan N, Slati F, Al-Sawalha NA
Pharmacology 2021;106(9-10):462-468. Epub 2021 Aug 10 doi: 10.1159/000518440. PMID: 34515227Free PMC Article
Sweeney RM, McAuley DF
Lancet 2016 Nov 12;388(10058):2416-2430. Epub 2016 Apr 28 doi: 10.1016/S0140-6736(16)00578-X. PMID: 27133972Free PMC Article
Jayaprakash B, Sandhya S, Anithakumari K
J Assoc Physicians India 2009 Jul;57:535-6. PMID: 20329418
Walsh TJ
Infect Dis Clin North Am 1989 Mar;3(1):43-52. PMID: 2647833
Yaffe BH, Korelitz BI
Am J Gastroenterol 1983 Aug;78(8):493-4. PMID: 6136183

Prognosis

Alexandre AT, Vale A, Gomes T
Sarcoidosis Vasc Diffuse Lung Dis 2019;36(1):47-52. Epub 2019 May 1 doi: 10.36141/svdld.v36i1.7160. PMID: 32476936Free PMC Article
De Giacomi F, Vassallo R, Yi ES, Ryu JH
Am J Respir Crit Care Med 2018 Mar 15;197(6):728-736. doi: 10.1164/rccm.201710-1967CI. PMID: 29206477
Brownback KR, Thomas LA, Simpson SQ
Curr Opin Infect Dis 2014 Aug;27(4):322-8. doi: 10.1097/QCO.0000000000000072. PMID: 24977681
Marchand E, Cordier JF
Orphanet J Rare Dis 2006 Apr 6;1:11. doi: 10.1186/1750-1172-1-11. PMID: 16722612Free PMC Article
Kitaichi M, Izumi T
Curr Opin Pulm Med 1995 Sep;1(5):417-24. PMID: 9363104

Clinical prediction guides

Alexandre AT, Vale A, Gomes T
Sarcoidosis Vasc Diffuse Lung Dis 2019;36(1):47-52. Epub 2019 May 1 doi: 10.36141/svdld.v36i1.7160. PMID: 32476936Free PMC Article
Tejerina EE, Abril E, Padilla R, Rodríguez Ruíz C, Ballen A, Frutos-Vivar F, Lorente JÁ, Esteban A
Mycoses 2019 Aug;62(8):673-679. Epub 2019 Jun 9 doi: 10.1111/myc.12927. PMID: 31177621
Writing Committee for the PROBESE Collaborative Group of the PROtective VEntilation Network (PROVEnet) for the Clinical Trial Network of the European Society of Anaesthesiology, Bluth T, Serpa Neto A, Schultz MJ, Pelosi P, Gama de Abreu M; PROBESE Collaborative Group, Bluth T, Bobek I, Canet JC, Cinnella G, de Baerdemaeker L, Gama de Abreu M, Gregoretti C, Hedenstierna G, Hemmes SNT, Hiesmayr M, Hollmann MW, Jaber S, Laffey J, Licker MJ, Markstaller K, Matot I, Mills GH, Mulier JP, Pelosi P, Putensen C, Rossaint R, Schmitt J, Schultz MJ, Senturk M, Serpa Neto A, Severgnini P, Sprung J, Vidal Melo MF, Wrigge H
JAMA 2019 Jun 18;321(23):2292-2305. doi: 10.1001/jama.2019.7505. PMID: 31157366Free PMC Article
Hage CA, Knox KS, Davis TE, Wheat LJ
Curr Opin Pulm Med 2011 May;17(3):167-71. doi: 10.1097/MCP.0b013e3283447b60. PMID: 21311331
Pulpeiro JR, Armesto V, Varela J, Corredoira J
Br J Radiol 1991 Sep;64(765):798-801. doi: 10.1259/0007-1285-64-765-798. PMID: 1913042

Recent systematic reviews

Dragos C, Joseph C, Elwell H, Dey M, Kouranloo K
Rheumatol Int 2024 Oct;44(10):1875-1886. Epub 2024 May 20 doi: 10.1007/s00296-024-05611-7. PMID: 38769126Free PMC Article
Kouranloo K, Ashley A, Zhao SS, Dey M
Rheumatol Int 2023 Jun;43(6):1023-1032. Epub 2023 Jan 8 doi: 10.1007/s00296-022-05266-2. PMID: 36617363Free PMC Article
Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN
Cochrane Database Syst Rev 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. PMID: 29297205Free PMC Article
Khushman M, Morris MI, Diaz L, Goodman M, Pereira D, Fuller K, Garcia-Buitrago M, Moshiree B, Zelaya S, Nayer A, Benjamin CL, Komanduri KV
Transplant Proc 2017 Mar;49(2):373-377. doi: 10.1016/j.transproceed.2016.12.012. PMID: 28219601
Leone S, Nicastri E, Giglio S, Narciso P, Ippolito G, Acone N
Int J Infect Dis 2010 Apr;14(4):e283-91. Epub 2009 Aug 4 doi: 10.1016/j.ijid.2009.05.016. PMID: 19656712

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...